Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Liabilities and Shareholders Equity (2016 - 2025)

Sanofi's Liabilities and Shareholders Equity history spans 4 years, with the latest figure at $127.2 billion for Q4 2018.

  • For Q4 2018, Liabilities and Shareholders Equity rose 8.19% year-over-year to $127.2 billion; the TTM value through Dec 2021 reached $127.2 billion, changed 0.0%, while the annual FY2018 figure was $131.6 billion, 16.74% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2018 was $127.2 billion at Sanofi, up from $117.5 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $127.2 billion in Q4 2018 and bottomed at $112.2 billion in Q4 2015.
  • The 4-year median for Liabilities and Shareholders Equity is $115.3 billion (2016), against an average of $117.5 billion.
  • The largest annual shift saw Liabilities and Shareholders Equity increased 0.77% in 2016 before it grew 8.19% in 2018.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $112.2 billion in 2015, then increased by 0.77% to $113.0 billion in 2016, then grew by 4.0% to $117.5 billion in 2017, then rose by 8.19% to $127.2 billion in 2018.
  • Per Business Quant, the three most recent readings for SNY's Liabilities and Shareholders Equity are $127.2 billion (Q4 2018), $117.5 billion (Q4 2017), and $113.0 billion (Q4 2016).